News

I-SPY 2 graduates two neoadjuvant treatments to phase III trials

View on the News

pCR ‘not a clinically meaningful endpoint’

These two multicenter trials may ultimately lead to changes in treatment in the years ahead. The investigators created a collaborative culture around these studies, and the work that appears in the Journal would not have been possible absent that spirit of cooperation and collective creativity. However, these trials were not designed to predict the ultimate success of either neratinib or carboplatin-veliparib in improving disease-free or overall survival. Instead, they predict a positive result with the use of pathological complete response rate as an endpoint in a definitive neoadjuvant study.

Clinicians should remember that pathological complete response rate itself is not a clinically meaningful endpoint; its value is as a surrogate for outcome. Although pathological complete response rate is consistently associated with a decreased risk of relapse and death for individual patients, even substantial improvements in pathological complete response rate in neoadjuvant trials have not consistently translated into improvement in long-term outcomes. The reasons for this are myriad, including the molecular heterogeneity of breast cancer and the possible effect of postsurgical interventions. Most importantly, pathological complete response rate will correlate with survival outcomes only if the neoadjuvant agents leading to the improvement in pathological complete response also eradicate resistant tumor clones.

At this time, improvements in pathological complete response rates as reported in neoadjuvant studies – whether the studies are exploratory, such as I-SPY 2, or more definitive – should not change clinical practice; rather, we should wait for the definitive clinical trials that result from them. Nonetheless, standard neoadjuvant therapy remains a sound clinical approach with the potential to individualize therapy. It also remains a valuable research tool that has the potential to help us develop hypotheses and explore mechanisms of drug resistance.

Lisa A. Carey, MD., is with the UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, and Eric P. Winer, MD, is with the Breast Oncology Program, Dana-Farber Cancer Center, Boston. These comments are excerpted from an editorial (N Engl J Med. 2016 July 7. doi: 10.1056/NEJMe1603691).


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

References

The rate of grade 3 or greater hematologic toxic effects in this trial arm was higher in patients treated with veliparib-carboplatin, with neutropenia rates of 71% versus 2% for controls. Adverse events occurring only in patients on veliparib-carboplatin were thrombocytopenia in 21%, anemia in 28%, and febrile neutropenia in 1%. Among patients who had received the combination, toxic effects were higher during doxorubicin-cyclophosphamide therapy.

HR-negative disease

Patients with hormone receptor–negative disease received standard neoadjuvant chemotherapy with 12 weekly cycles of paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide as described before, with or without oral neratinib 240 mg per day. Patients in the control group who had HER2-positive cancers also received trastuzumab for the first 12 weeks with a loading dose of 4 mg per kilogram of body weight in the first cycle, followed by a maintenance dose of 2 mg per kilogram in cycles 2 through 12.

Surgery, including sentinel-node dissection in patients with node-negative cancer and axillary-node dissection in those with node-positive cancer at diagnosis, was performed according to NCCN and local practice guidelines, and adjuvant radiation and endocrine therapy were recommended according to standard guidelines.

The protocol was modified to included diarrhea prophylaxis with loperamide among patients assigned to receive neratinib.

A total of 127 patients were assigned to neratinib, and 115 of these patients were evaluable for response. Controls included 84 patients, of whom 78 were evaluable. At baseline, more patients in the neratinib group had HER2-positive tumors. Neratinib reached the prespecified efficacy threshold only within the HER2-positive, HR-negative group.

Diarrhea was the most common adverse event, with grade 3 or greater diarrhea occurring among 38% of patients assigned to neratinib. Vomiting and elevated liver enzymes were also more frequent with neratinib.

I-SPY 2 is supported by QuantumLeap Healthcare Collaborative, the Foundation for the National Institutes of Health (from 2010 through 2012) and the National Cancer Institute. Dr. Park reported receiving lecture fees and travel support from Genentech and Pfizer, and receiving royalties from patents. Dr. Rugo reported grants to her institution from BioMarin, and unpaid steering committee participation for BioMarin and AbbVie. Multiple co-authors reported financial relationships of various kinds.

Pages

Recommended Reading

ASCO issues guidelines for HR+ metastatic breast cancer
MDedge ObGyn
Exercise linked to fewer cardiovascular events in nonmetastatic breast cancer patients
MDedge ObGyn
Targeting vagal activity could improve breast cancer survival
MDedge ObGyn
VIDEO: Doctors should be challenged to extend AIs
MDedge ObGyn
Webcast: Oral contraceptives and breast cancer: What’s the risk?
MDedge ObGyn
VIDEO: Direct-to-patient study empowers patients, accelerates research
MDedge ObGyn
Liquid biopsies prove useful alternative to tissue biopsies
MDedge ObGyn
Ethnic groups differ in BRCA risk management
MDedge ObGyn
Adjuvant AI therapy for breast cancer: 10 years is superior to 5 years
MDedge ObGyn
In-person, telephone genetic counseling yield similar outcomes
MDedge ObGyn